Invivyd Announces PEMGARDA™ ( pemivibart ) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial - Invivyd ( NASDAQ:IVVD )

3 weeks ago

In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% rate of confirmed symptomatic COVID-19 compared to an 11.9% rate for participants receiving placebo, an 84% ...

Ticker	Sentiment	Impact
IVVD	Neutral	10 %